Cochrane · systematic review · CD008495
Methotrexate monotherapy versus methotrexate combination therapy with non‐biologic disease modifying anti‐rheumatic drugs for rheumatoid arthritis
Katchamart, W, Trudeau, J, Phumethum, V, et al. · Cochrane Database of Systematic Reviews · 2010 · Cochrane Library
MusculoskeletalAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
7
current version
GRADE rated
7
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 2 · 28.6%Low 1 · 14.3%Moderate 4 · 57.1%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
MTX combination compared to MTX monotherapy for Rheumatoid arthritis
Population: patients with Rheumatoid arthritis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
ACR 50 response of DMARDs naive patients Number of responders MTX combination vs MTX monotherapy | RR 1.76 [0.64, 4.85] | 2 studies · 127 participants | Low Downgraded: risk of bias |
ACR 50 response of MTX inadequate responders number of responders MTX combination vs MTX monotherapy | RR 4.54 [2.51, 8.2] | 3 studies · 404 participants | Moderate Downgraded: risk of bias |
ACR 50 response of non‐MTX DMARDs inadequate responders number of responders MTX combination vs MTX monotherapy | RR 1.68 [0.94, 2.99] | 2 studies · 158 participants | Moderate Downgraded: risk of bias |
Withdrawal due to lack of efficacy or toxicity of DMARDs naive patients number of withdrawals MTX combination vs MTX monotherapy | RR 1.16 [0.7, 1.93] | 5 studies · 405 participants | Moderate Downgraded: risk of bias |
Withdrawal due to lack of efficacy or toxicity of MTX inadequate responders number of withdrawals MTX combination vs MTX monotherapy | RR 0.86 [0.49, 1.51] | 3 studies · 476 participants | Moderate Downgraded: risk of bias |
Withdrawal due to lack of efficacy or toxicity of non‐MTX DMARDs inadequate responders number of withdrawals MTX combination vs MTX monotherapy | RR 0.75 [0.41, 1.35] | 5 studies · 329 participants | Very low Downgraded: risk of bias |
Withdrawal due to adverse reactions (Pooled across regimens) number of withdrawals MTX combination vs MTX monotherapy | RR 1.59 [1.2, 2.12] | 17 studies · 1624 participants | Very low Downgraded: risk of bias |